# Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0108+C2407 in Patients With Dyslipidemia

> **NCT06955104** · PHASE3 · COMPLETED · sponsor: **JW Pharmaceutical** · enrollment: 145 (actual)

## Conditions studied

- Dyslipidemia

## Interventions

- **DRUG:** JW0108 + C2407
- **DRUG:** JW0108 + C2407 placebo

## Key facts

- **NCT ID:** NCT06955104
- **Lead sponsor:** JW Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-04-03
- **Primary completion:** 2025-07-30
- **Final completion:** 2025-07-30
- **Target enrollment:** 145 (ACTUAL)
- **Last updated:** 2025-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06955104

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06955104, "Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0108+C2407 in Patients With Dyslipidemia". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06955104. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*